TH9507 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Compared to the United Monarchy, the historicity of the Kingdom of Israel and Judah is widely accepted by historians and archaeologists. Their destruction by the Assyrians and Babylonians respectively is also confirmed by archaeological evidence and extrabiblical sources. Christian Frevel argues that Yahwism was rooted in the culture of the Kingdom of Israel, who introduced it to the Kingdom of Judah via Ahab's expansions and sociopolitical cooperation, which was prompted by Hazael's conquests. Frevel has also argued that Judah was a 'vassal-like' state to Israel, under the Omrides. This theory has been rejected by other scholars, who argue that the archaeological evidence seems to indicate that Judah was an independent socio-political entity for most of the 9th century BCE. Avraham Faust argues that there was continued adherence to the 'ethos of egalitarianism and simplicity' in the Iron Age II (10th-6th century BCE). For example, there is minimal evidence of temples and complex tomb burials, despite Israel and Judah being more densely populated than the Late Bronze Age. Four-room houses remained the norm. In addition, royal inscriptions were scarce, along with imported and decorated pottery. According to William G. Dever, Israelite identity in the 9th-8th centuries BCE can be identified through a combination of archaeological and cultural traits that distinguish them from their neighbours.
=== Tokusou Combinations === Dekaranger Robo (デカレンジャーロボ, Dekarenjā Robo): The Dekarangers' first giant robot composed of the five main Deka Machines that wields the Signal Cannon, which allows it to perform the Justice Flasher (ジャスティスフラッシャー, Jasutisu Furasshā) finisher, and the Judgement Sword, which allows it to perform the Judgement Crash (ジャッジメントクラッシュ, Jajjimento Kurasshu) finisher. Super Dekaranger Robo (スーパーデカレンジャーロボ, Gattai Sūpā Dekarenjā Robo): The Super Tokusou Combination (超特捜合体, Chō Tokusō Gattai) of Dekaranger Robo and the Deka Bike that is equipped with a series of boosters. Its finishers are the Gatling Punch (ガトリングパンチ, Gatoringu Panchi) and the Dynamite Upper (ダイナマイトアッパー, Dainamaito Appā). Dekaranger Robo Full Blast Custom (デカレンジャーロボ フルブラストカスタム, Dekarenjā Robo Furu Burasuto Kasutamu): A combination of Dekaranger Robo and the Blast Buggy that wields the Blast Launcher (ブラストランチャー, Burasuto Ranchā) and the Blast Shield (ブラストシールド, Burasuto Shīrudo), which allows it to perform the Spinning Blast (スピニングブラスト, Supiningu Burasuto) attack. The Blast Launcher and Shield can also combine to form the Full Blast Launcher (フルブラストランチャー, Furu Burasuto Ranchā), which allows Dekaranger Robo to perform the Full Blast (フルブラスト, Furu Burasuto) finisher. This formation appears exclusively in the film Tokusou Sentai Dekaranger The Movie: Full Blast Action.
== Key people == The Santa Monica-based startup was founded in September 2011 by Trevor Bezdek and former Facebook executives Doug Hirsch and Scott Marlette. Marlette was one of the first 20 employees at Facebook and built Facebook's photo application. In 2005, Hirsch was the Vice President of Product at Facebook, working closely with Mark Zuckerberg. Bezdek and Hirsch served as co-chief executive officers until April 2023, when they stepped down from those roles and technology executive Scott Wagner was appointed interim chief executive officer. Bezdek became chair of the board, while Hirsch took on the role of chief mission officer. In December 2024, GoodRx announced that healthcare executive Wendy Barnes would become president and chief executive officer effective January 1, 2025. As of 2025, Barnes serves as the company's CEO, while Trevor Bezdek and Scott Wagner serve as co-chairs of the board, and Doug Hirsch remains involved as a co-founder and senior executive.
Sources: en.wikipedia.org
== Structural studies == As of late 2007, 8 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1A0G, PDB: 1DAA, PDB: 1G2W, PDB: 2DAA, PDB: 2DAB, PDB: 3DAA, PDB: 4DAA, and PDB: 5DAA.
Alcohol: 6-12 h Marijuana: 1-24h A disadvantage of saliva based drug testing is that it is not approved by FDA or SAMHSA for use with DOT / Federal Mandated Drug Testing. Oral fluid is not considered a bio-hazard unless there is visible blood; however, it should be treated with care.
His plan fails and he rejoins Freeman's group. Freeman then finds Bubby stuck in his old test tube, who had also been betrayed by the military, along with Benry. Freeman reluctantly allows them to rejoin the group. The science team proceed to Black Mesa's Mixology Department, headed by Darnold (Logmore), who gives Freeman a potion that causes his missing arm to regrow into a machine gun. The team fight their way to the Lambda Complex, where they teleport to Xen. In Xen, they find Benry has grown into a giant and begins floating around the others, taunting them. Benry is revealed to be the source of the resonance cascade, transforming into a monstrous alien form and attacking the rest of the science team, who work together to eventually defeat him, by time traveling to the beginning of the game to retrieve their passports. After defeating Benry, Freeman is captured by the G-Man (Spaghoner), who thanks him for taking down Benry and invites him to the birthday party of Tommy, revealed to be the G-Man's adopted son. In the credits sequence, the science team and the G-Man celebrate Tommy's birthday at a Chuck E. Cheese, much to Freeman's despair. In a post-credits scene, Dr. Coomer calls Freeman and congratulates him for beating the game, thanking him for taking the science team with him on his adventure.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.